Compare XENE & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XENE | FHI |
|---|---|---|
| Founded | 1996 | 1955 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.3B |
| IPO Year | 2014 | 1998 |
| Metric | XENE | FHI |
|---|---|---|
| Price | $38.80 | $61.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 18 | 8 |
| Target Price | ★ $71.56 | $61.00 |
| AVG Volume (30 Days) | ★ 1.2M | 737.4K |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 2.42% |
| EPS Growth | N/A | ★ 58.82 |
| EPS | N/A | ★ 4.15 |
| Revenue | $311,000.00 | ★ $1,102,924,000.00 |
| Revenue This Year | N/A | $10.62 |
| Revenue Next Year | $1,985.11 | $3.61 |
| P/E Ratio | ★ N/A | $15.13 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.38 | $47.30 |
| 52 Week High | $72.66 | $67.38 |
| Indicator | XENE | FHI |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 50.30 |
| Support Level | $33.38 | $53.95 |
| Resistance Level | $39.92 | $66.80 |
| Average True Range (ATR) | 1.44 | 2.11 |
| MACD | 0.45 | -0.06 |
| Stochastic Oscillator | 39.58 | 39.31 |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Federated Hermes provides asset management services for institutional and individual investors. The firm had $911.6 billion in managed assets at the end of the second quarter of 2026, composed of equity (12%), multi-asset (less than 1%), fixed-income (11%), alternative (2%), and money market (74%) funds. The company's cash management operations are expected to generate around 52% of Federated's revenue this year, compared with 30%, 10%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).